ESTRO 2024 - Abstract Book

S996

Clinical - Gynaecology

ESTRO 2024

Material/Methods:

A total of 17 patients, encompassing 30 lesions, were included in this analysis. Among them, 15 patients had ovarian cancer, while 2 had cervical tumors. Nine patients had previously undergone multiple systemic regimens. Fourteen patients received bevacizumab before SBRT, with varying time intervals from the last administration. Stereotactic radiotherapy was the initial radiotherapy treatment for all but two patients, and nine lesions were treated with MRI-guided techniques. Up to three to five consecutive daily fractions were administered for a total of 20 nodal and 10 parenchymal lesions. Doses were prescribed at specific isodose levels, ranging from 25.5 Gy in 3 fractions to 50 Gy in 5 fractions based on metastasis location and organ at risk constraints.

Results:

Of the 30 lesions, 11 (36.6%) achieved a complete clinical response, while 16 (53.3%) demonstrated a partial response. Stable disease was observed in 2 (6.6%) lesions, and only 1 (3.3%) lesion showed progression. The overall response rate was 90%. With a median follow-up of 13 months (range 4-59 months), 13 out of 17 patients (76.5%) achieved local control of their disease. Acute toxicity was limited, with only two patients experiencing Grade 1 diarrhea and headache. No late toxicities were reported, and quality of life scores did not significantly differ between the pre-SBRT and first follow-up assessments.

Conclusion:

Fractionated stereotactic radiotherapy, administered with a short interval from bevacizumab, was well-tolerated and effective in this study. Further research on stereotactic radiotherapy in conjunction with targeted therapy is warranted in the challenging context of oligometastatic, oligorecurrent, and oligopersistent gynaecological tumors.

Keywords: Stereotactic radiotherapy, oligometastases

633

Mini-Oral

Toripalimab combined with definitive CCRT for locally advanced cervical squamous cell carcinoma.

Dan Ou, Rong Cai, Weixiang Qi, Jiayi Chen, Haoping Xu

Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Department of Radiation Oncology, Shanghai, China

Purpose/Objective:

This phase Ⅰ / Ⅱ trial (ChiCTR2000032879) aimed to assess the safety and efficacy of toripalimab combined with chemoradiotherapy for locally advanced cervical squamous cell carcinoma.